|Bid||41.3500 x 800|
|Ask||41.4500 x 800|
|Day's range||40.8500 - 42.0000|
|52-week range||27.1500 - 68.0500|
|PE ratio (TTM)||N/A|
|Earnings date||31 Oct 2018 - 5 Nov 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||80.21|
Investors need to pay close attention to Global Blood (GBT) stock based on the movements in the options market lately.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Global Blood Therapeutics, Inc. (“Global Blood” or “the Company”) (NASDAQ: GBT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Stat published an article about Global Blood, claiming that there are “important risks that investors might be glossing over” about the likelihood of Global Blood’s new drug for sickle cell disease, voxelotor, being approved by the FDA.
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Global Blood Therapeutics, Inc. resulting from allegations that Global Blood may have issued materially misleading business information to the investing public.
NEW YORK, Sept. 13, 2018-- Bragar Eagel & Squire, P.C. is investigating potential claims against Global Blood Therapeutics, Inc.. Our investigation concerns whether Global Blood has violated the federal ...
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2018-- Global Blood Therapeutics, Inc. today announced that it will present at the 2018 Morgan Stanley Global Healthcare Conference in New York City on Friday, September ...
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2018-- Global Blood Therapeutics, Inc. today announced that, on September 4, 2018, the compensation committee of the Company’ s board of directors granted five new ...
Healthcare Providers, Patient Advocates and Policy Makers Will Discuss Issues Impacting SCD Community During National SCD Awareness Month. Livestream of Conference Will Be Available through Collaboration ...
Global Blood Therapeutics, Inc. (GBT) (GBT) announced today that it has entered into an exclusive worldwide licensing agreement with F. Hoffmann-La Roche Ltd. for the development and commercialization of inclacumab, a novel fully human monoclonal antibody against P-selectin. Under the terms of the agreement, GBT will be responsible for all development, manufacturing, and commercialization of inclacumab worldwide.
Global Blood Therapeutics, Inc. (GBT) (GBT) today announced the appointment of Heidi L. Wagner as senior vice president, government affairs and policy. Ms. Wagner joins GBT from Alexion Pharmaceuticals, where she was senior vice president, global government affairs. At GBT, Ms. Wagner will create and lead the Company’s government affairs and public policy function, initially focused on concerns related to the sickle cell disease (SCD) community.
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018-- Global Blood Therapeutics, Inc. today announced that it will present at the 2018 Wedbush PacGrow Healthcare Conference in New York City on Tuesday, August 14 ...
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2018-- Global Blood Therapeutics, Inc. today announced that, on August 1, 2018, the compensation committee of the Company’ s board of directors granted two new employees ...
On a per-share basis, the South San Francisco, California-based company said it had a loss of 78 cents. The results exceeded Wall Street expectations. The average estimate of nine analysts surveyed by ...
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2018-- Global Blood Therapeutics, Inc. today reported business progress and financial results for the second quarter ended June 30, 2018.. "We continue to advance ...
SOUTH SAN FRANCISCO, Calif., July 03, 2018-- Global Blood Therapeutics, Inc. today announced that, on July 2, 2018, the compensation committee of the Company’ s board of directors granted four new employees ...
Yesterday, Global Blood Therapeutics (GBT), a clinical-stage biopharmaceutical company, announced positive top-line data for its Phase 3 HOPE study of its Voxelotor therapy for sickle cell disease. GBT stock rose by ~15.6% yesterday and was up ~3.7% in pre-market trading today.
The company is betting that recent trial results, which were mostly positive, are enough to score a drug approval — and is pausing the trial.
Investors in Global Blood Therapeutics (GBT) need to pay close attention to the stock based on moves in the options market lately.
Global Blood Therapeutics, Inc. (GBT) (GBT) today announced the completion of a planned review of Part A of the Phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study, which is evaluating voxelotor for the treatment of sickle cell disease (SCD). On the primary endpoint (the proportion of patients with greater than 1 g/dL increase in hemoglobin versus baseline), a statistically significant increase was demonstrated with voxelotor at both the 1500 mg and 900 mg doses after 12 weeks of treatment versus placebo.